NCT05472532Completed
Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)
Source: ClinicalTrials.gov · Last updated 20 Nov 2025
Brief summary (registry, in English)
A variety of in vivo experimental models have been established for the studies of human cancer using both cancer cell lines and patient-derived xenografts (PDXs). In order to meet the aspiration of precision medicine, the in vivo murine models have been widely adopted. However, common constraints such as high cost, long duration of experiments, and low engraftment efficiency remained to be resolved. The chick embryo chorioallantoic membrane (CAM) is an alternative model to overcome some of these limitations. The chick CAM is shown to be a robust model for both the inoculation of cell lines and grafting of patient tumors for drug therapy evaluations and target genes/pathways analysis. The start-up INOVOTION has developed a unique, highly sensitive and reproducible CAM assay to graft human cancer cells/tumors in the chicken egg environment. INOVOTION's technology was validated for over 55 human tumor cell lines, including carcinomas, gliomas and melanomas, as well as over 30 reference drugs currently on the market. At INOVOTION, the graft of human cancer cells on the chicken CAM is currently conducted manually. To scale-up, the process was recently automated. The automation performance was assessed on cancer cells lines. The objective of this study is to demonstrate that the automation of the INOVOTION process enables tumors' proliferation using patient samples (from tumor samples or circulating tumor cells) as grafting material.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 101 (actual)
- First submitted
- 7 Jul 2022
- Start date
- 14 Feb 2023
- Primary completion date
- 14 Feb 2025
- Lead sponsor
- Hospices Civils de Lyon
- NCT number
- NCT05472532
What you commit to
- Study type: Interventional
- Participants enrolled: 101
- From 14 Feb 2023 to the primary completion date, 14 Feb 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion Criteria for all cohorts \* :
- Age \> 18
- Signed consent
- Inclusion criteria for the "Prostate" cohort:
- prostate adenocarcinoma histologically proven
- metastatic situation
- at least 2 metastatic sites
- Evolutionary disease that requires a new treatment
- Inclusion criteria for the "Breast" cohort:
- HER2+ or RH+ breast adenocarcinoma histologically proven
- metastatic situation
- at least 2 metastatic sites
- Evolutionary disease that requires a new treatment
- Inclusion criteria for the "Lung" cohort:
- Non Small Lung cancer histologically proven
- metastatic situation
- at least 2 metastatic sites
- Evolutionary disease that requires a new treatment
- Inclusion criteria for "Ovarian" cohort:
- Ovarian cancer histologically proven
- Presence of peritoneal carcinomatosis (stage IIIC or IV); with or without presence of peritoneal fluid
- Inclusion criteria for "Colo-Rectal" cohort:
- Colo-rectal cancer histologically proven
- Presence of peritoneal carcinomatosis, with or without presence of peritoneal fluid
- Evolutionary disease that requires a new treatment
- Inclusion criteria for "Gastric" cohort:
- Gastric cancer histologically proven
- Presence of peritoneal carcinomatosis, with or without presence of peritoneal fluid
- Exclusion Criteria for all cohorts \* :
- Weight \<50kg
- Parallel participation in a doubled blinded study
- Brain or ganglionary metastasis only
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Lyon Sud - Department of Medical Oncology Coordinator of this site? Confirm its status | Pierre-Bénite | France | Unknown status |
| Centre Hospitalier Lyon-Sud Coordinator of this site? Confirm its status | Pierre-Bénite | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.